Obesity is a chronic disease, so short-term change is only one part of the evidence picture
Nausea is the most common side-effect GLP-1 symptom, followed by vomiting, sour burps, heartburn and gastroparesis Side-Effect Profile of GLP-1s, from Worst to Best (% reflects estimated number of patients with GI side-effects) 50% Semaglutide (Ozempic, Rybelsus, Wegovy) 40% Tirzepatide (Saxenda, Mounjaro) 40% Liraglutide (Victoza, Saxenda) 30% Lixisenatide (Adlyxin USA, Lyxumia UK) 10% Dulaglutide (Trulicity) 10% Exenatide (Byetta, Bydureon) Wegovy, Mounjaro, and Saxenda FDA-approved for weight loss
6.3 Clinical applications in cardiovascular disease prevention Recent American College of Cardiology/American Heart Association guidelines advocate for the use of GLP-1RAs in patients with T2DM at high risk of atherosclerotic cardiovascular disease (ASCVD), irrespective of well-controlled glucose levels, based on the clinical trials mandated by FDA-issued industry guidelines in December 2008 to assess the cardiovascular effects of new diabetic therapies (247)
Always consult with a qualified healthcare provider before starting, stopping, or changing any medication or treatment
In clinical trials, weight loss with GLP-1 medications tends to follow a predictable curve: rapid early losses during drug initiation and dose increases, a gradual slowing and eventual plateau
Ian Stratton, Age 57, Everett, WA We all want to be the best version of ourselves, both physically and mentally